Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine

There is much current excitement about the potential of cancer immunotherapy. WT1 is high on the National Cancer Institute’s list of priority antigens for immune therapy. In this chapter we describe a protocol for a clinical trial using a WT1 peptide-based cancer vaccine.
Source: Springer protocols feed by Cancer Research - Category: Cancer & Oncology Source Type: news